KR960702476A - Lhrh 길항제(lhrh antagonists) - Google Patents
Lhrh 길항제(lhrh antagonists)Info
- Publication number
- KR960702476A KR960702476A KR1019950705129A KR19950705129A KR960702476A KR 960702476 A KR960702476 A KR 960702476A KR 1019950705129 A KR1019950705129 A KR 1019950705129A KR 19950705129 A KR19950705129 A KR 19950705129A KR 960702476 A KR960702476 A KR 960702476A
- Authority
- KR
- South Korea
- Prior art keywords
- lys
- antid
- complex
- carrier
- lhrh antagonist
- Prior art date
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims abstract 10
- 239000002474 gonadorelin antagonist Substances 0.000 claims 7
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 4
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Natural products N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims 3
- 102000006771 Gonadotropins Human genes 0.000 claims 2
- 108010086677 Gonadotropins Proteins 0.000 claims 2
- 229930003779 Vitamin B12 Natural products 0.000 claims 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 2
- 235000000639 cyanocobalamin Nutrition 0.000 claims 2
- 239000011666 cyanocobalamin Substances 0.000 claims 2
- 229960002104 cyanocobalamin Drugs 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002622 gonadotropin Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000011715 vitamin B12 Substances 0.000 claims 2
- 235000019163 vitamin B12 Nutrition 0.000 claims 2
- OAJLVMGLJZXSGX-SLAFOUTOSA-L (2s,3s,4r,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7 Chemical compound [Co+3].O[C@H]1[C@@H](O)[C@@H]([CH2-])O[C@@H]1N1C2=NC=NC(N)=C2N=C1.[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O OAJLVMGLJZXSGX-SLAFOUTOSA-L 0.000 claims 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical class CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims 1
- 229940051881 anilide analgesics and antipyretics Drugs 0.000 claims 1
- 150000003931 anilides Chemical class 0.000 claims 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 claims 1
- 150000001556 benzimidazoles Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- -1 cobalamide Chemical compound 0.000 claims 1
- WBSXYJYELWQLCJ-UHFFFAOYSA-K cobalt(3+);[5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1h-corrin-21-id-3-yl]propanoylamino]propan-2 Chemical compound O.[OH-].[Co+3].OCC1OC(N2C3=CC(C)=C(C)C=C3N=C2)C(O)C1OP([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O WBSXYJYELWQLCJ-UHFFFAOYSA-K 0.000 claims 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 claims 1
- 235000006279 cobamamide Nutrition 0.000 claims 1
- 239000011789 cobamamide Substances 0.000 claims 1
- 125000002235 cyanocobalamin group Chemical group 0.000 claims 1
- 238000005202 decontamination Methods 0.000 claims 1
- 230000003588 decontaminative effect Effects 0.000 claims 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 claims 1
- CKTNHGVJKUQEBM-UHFFFAOYSA-N ethylazanide Chemical compound CC[NH-] CKTNHGVJKUQEBM-UHFFFAOYSA-N 0.000 claims 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000006747 infectious mononucleosis Diseases 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 claims 1
- 235000007672 methylcobalamin Nutrition 0.000 claims 1
- 239000011585 methylcobalamin Substances 0.000 claims 1
- 238000009806 oophorectomy Methods 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical class CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 description 1
- 108010083551 iturelix Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 신규한 LHRH 길항제 및 이들 길항제와 VB12 간의 복합체를 제공한다. 본 발명은 특히 LHRH길항제의 경구투여에 유용하다. 본 발명의 길항제는 안티드-1, 안티드-2 및 안티드-3으로 이루어진 군으로부터 선택된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 랫트의 뇌하수체 세포로부터의 안티드(ANTIDE), 1H의 LHRH-자극방츨의 억제를 알아보기 위한 생체밖 생물검정에 의해 결정된 중간 억제농도(IC50)를 보여주는 그래프이다.
제2도는 랫트의 뇌하수체 세포로부터의 안티드, 안티드-3 및 이것의 VB12-컨쥬게이트에 의한 1H의 LHRH-자극 방출의 억제를 알아보기 의한 생체밖 생을 검정을 보여주는 그래프이다.
Claims (9)
- N-Ac-D-Nal(2), D-Phe(pCl), D-Pal(3), Ser, Lys(Nic), D-Lys, Leu, Lys(iPr), Pro, D-Ala-NH2(D-Lys6안티드 또는 안티드-1); N-Ac-D-Nal(2), D-Phe(pCl), D-Pal(3), Ser, Lys, D-Lys(Nic), Leu, Lys(Tr), Pro, D-Ala-NH2(Lys5안티드 또는 안티드-2) 및 N-Ac-D-Nal(2), D-Phe(pCl), D-Pal(3), Ser, Lys(Nic), D-Lys(Nic), Leu, Lys, Pro, D-Ala-NH2(Lys8안티드 또는 안티드-3)로 이루어진 군으로부터 선택되는 LHRH 길항제.
- 환자의 화학적 난소제거 및/또는 고나도트로핀 의존적 장애의 치료에서의 이용을 위한 복합체에 있어서, 복합체는 결합제기를 통하여 비타민 B12나 이것의 유사체인 담체에 결합된 LHRH 길항제로 이루어지고 결합제기는 LHRH 길항제가 생체내에서 담체로부터 절단되는 것을 특징으로 하는 복합체.
- 제2항에 있어서, LHRH 길항제는 안티드-1, 안티드-2 및 안티드-3으로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 복합체.
- 제3항에 있어서, LHRH 길항제는 안티드-3인 것을 특징으로 하는 복합체.
- 제2항 내지 제4항 중 어느 한 항에 있어서, 하나 이상의 LHRH 길항제가 담체에 결합되어 있는 것을 특징으로 하는 복합체.
- 제2항 내지 제5항 중 어느 한 항에 있어서, 담체는 시아노코발아민, 아쿠오코발아민, 아데노실코발아민, 메틸코발아민, 히드록시코발아민, 시아노코발아민, 카바날리드, 5-o-메틸 벤질코발아민, 상기한 모두의 데스디메틸, 모노에틸아미드 및 메틸아미드 유사체, 코발아미드, 조효소 B12, 5'-디옥시아데노실코발아민, 클로로코발아민, 술피토코발아민, 니트로코발아민, 티오시아나토코발아민, 벤즈이미다졸유도체, 아데노실시아노코발아민, 코발아민 락톤, 코발아민 락탐 및 아닐리드의 유사체와 동족체, 비타민 B12나 이것의 유사체의 에틸아미드, 프로피온아미드, 모노카르복실산 및 디카르복실산 유도체로 이루어진 군으로부터 선택되는 것을 특징으로 하는 복합체.
- 제2항 내지 제6항 중 어느 한 항에 있어서, LHRH 길항제는 티올-절단할 수 있는 교차-결합제를 통해 당체에 결합되는 것을 특징으로 하는 복합체.
- 제6항에 있어서, LHRH 길항제는 이황화 결합에 의해 담체에 결합되는 것을 특징으로 하는 복합체.
- 환자의 화학적 난소제거 및/또는 고나도트로핀 의존적 장애의 치료방법에 있어서, 환자에게 제2항 내지 제8항 중 어느 한 항에 따른 복합체의 유효량을 투여하는 것으로 이루어진 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPL888093 | 1993-05-20 | ||
| AUPL8880 | 1993-05-20 | ||
| PCT/AU1994/000262 WO1994028015A1 (en) | 1993-05-20 | 1994-05-20 | Lhrh antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR960702476A true KR960702476A (ko) | 1996-04-27 |
Family
ID=3776905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950705129A KR960702476A (ko) | 1993-05-20 | 1994-05-20 | Lhrh 길항제(lhrh antagonists) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5863900A (ko) |
| EP (1) | EP0698040A4 (ko) |
| JP (1) | JPH08510260A (ko) |
| KR (1) | KR960702476A (ko) |
| CA (1) | CA2163225A1 (ko) |
| RU (1) | RU2130464C1 (ko) |
| SG (1) | SG50426A1 (ko) |
| WO (1) | WO1994028015A1 (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5574018A (en) * | 1994-07-29 | 1996-11-12 | Amgen Inc. | Conjugates of vitamin B12 and proteins |
| US5843901A (en) * | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| EP1007533B1 (en) | 1996-08-27 | 2005-06-22 | University Of Utah Research Foundation | Bioconjugates and delivery of bioactive agents |
| AUPP405098A0 (en) * | 1998-06-12 | 1998-07-02 | Access Pharmaceuticals Australia Pty Limited | Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals |
| FR2822834B1 (fr) * | 2001-04-02 | 2005-02-25 | Flamel Tech Sa | Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation |
| FR2843117B1 (fr) * | 2002-07-30 | 2004-10-15 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques |
| GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
| FR2855521B1 (fr) * | 2003-05-28 | 2005-08-05 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques. |
| US7232805B2 (en) * | 2003-09-10 | 2007-06-19 | Inflabloc Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
| FR2860516B1 (fr) * | 2003-10-03 | 2006-01-13 | Flamel Tech Sa | Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques |
| FR2862536B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
| WO2008115805A2 (en) * | 2007-03-19 | 2008-09-25 | Inflabloc Pharmaceuticals, Inc. | Cobalamin taxane bioconjugates |
| WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
| KR20140026396A (ko) | 2011-03-08 | 2014-03-05 | 어섹스 팔마큐티칼스 인코포레이티드 | 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU587658B2 (en) * | 1985-10-10 | 1989-08-24 | Access Pharmaceuticals Australia Pty Limited | Oral delivery of biologically active substances bound to vitamin b12, or analogues thereof |
| NZ217821A (en) * | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
| US4935491A (en) * | 1987-08-24 | 1990-06-19 | Board Of Regents, The University Of Texas System | Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine |
| DK163689A (da) * | 1988-04-08 | 1989-10-30 | Sandoz Ag | Peptidderivater |
| US5169935A (en) * | 1990-06-20 | 1992-12-08 | The Salk Institute For Biological Studies | Method of making peptides |
-
1994
- 1994-05-20 WO PCT/AU1994/000262 patent/WO1994028015A1/en not_active Application Discontinuation
- 1994-05-20 SG SG1996001146A patent/SG50426A1/en unknown
- 1994-05-20 KR KR1019950705129A patent/KR960702476A/ko not_active Application Discontinuation
- 1994-05-20 RU RU95122703A patent/RU2130464C1/ru active
- 1994-05-20 CA CA002163225A patent/CA2163225A1/en not_active Abandoned
- 1994-05-20 EP EP94916085A patent/EP0698040A4/en not_active Withdrawn
- 1994-05-20 JP JP7500011A patent/JPH08510260A/ja active Pending
-
1995
- 1995-05-20 US US08/537,941 patent/US5863900A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08510260A (ja) | 1996-10-29 |
| RU2130464C1 (ru) | 1999-05-20 |
| US5863900A (en) | 1999-01-26 |
| SG50426A1 (en) | 1998-07-20 |
| EP0698040A1 (en) | 1996-02-28 |
| CA2163225A1 (en) | 1994-12-08 |
| EP0698040A4 (en) | 1999-01-07 |
| WO1994028015A1 (en) | 1994-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960702476A (ko) | Lhrh 길항제(lhrh antagonists) | |
| KR910000703A (ko) | 테트라졸 자극성 아미노산 수용체의 길항물질 | |
| Sundberg et al. | The effect of various prostaglandins and a prostaglandin synthetase inhibitor on rat anterior pituitary cyclic AMP levels and hormone release in vitro | |
| BR9808928A (pt) | Complexo molecular e liberação controlada dealfa hidroxiácidos | |
| BR9810340A (pt) | Sìntese e uso de compostos retinóides com atividades de hormÈnio negativo e/ou antagonistas | |
| EP1065203A3 (en) | Heterocyclic compounds as retinoic acid receptor antagonists | |
| FI20000172A (fi) | Itse-emulgoituvan valmisteen muodossa oleva farmaseuttinen koostumus happamia lipoifiilisia yhdisteitä varten | |
| RU95122703A (ru) | Антагонисты лг-рилизинг фактора (l hph) | |
| Barberis | [3H] Vasopressin binding to rat hippocampal synaptic plasma membrane: Kinetic and pharmacological characterization | |
| ATE370974T1 (de) | St rkederivate, st rke-wirkstoff-konj ugate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| Kwok et al. | Endomorphins decrease heart rate and blood pressure possibly by activating vagal afferents in anesthetized rats | |
| Clark et al. | Downregulation of the AT1A receptor by pharmacologic concentrations of Angiotensin-(1-7) | |
| Bennett et al. | How does nitroglycerin induce vascular smooth muscle relaxation? | |
| Funada et al. | Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system | |
| WO2001083693A8 (en) | Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses | |
| Lee et al. | Peptide inhibitor of morphine-and beta-endorphin-induced analgesia. | |
| Davis et al. | Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid CU1+ | |
| Pasquier et al. | Increased adenylate cyclase catalytic activity explains how estrogens “in vivo” promote lipolytic activity in rat white fat cells | |
| Satoh et al. | Sodium nitroprusside stimulates noradrenaline release from rat hippocampal slices in the presence of dithiothreitol | |
| KR850000920A (ko) | 합성 폴리펩타이드 | |
| Chaurasia et al. | Nonpeptide peptidomimetic antagonists of the neuropeptide Y receptor: benextramine analogs with selectivity for the peripheral Y2 receptor | |
| Grider | Regulation of excitatory neural input to longitudinal intestinal muscle by myenteric interneurons | |
| HOERMANN et al. | Role of subunit sialic acid in hepatic binding, plasma survival rate, and in vivo thyrotropic activity of human chorionic gonadotropin | |
| Umemura et al. | Regulation of renal cellular cAMP levels by prostaglandins and α2-adrenoceptors: microdissection studies | |
| KR970015597A (ko) | 비오틴 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |